In several epidemiological studies, it was suggested that a high titer of cytomegalovirus (CMV) antibody meant CMV reactivation, and that this condition was a determinant of coronary artery disease (CAD). The purpose of this study was to investigate both the prevalence of the CMV infections in our study population and whether high CMV seropositivity is a determinant of CAD. Blood samples from 179 (58 female, 121 male) individuals being evaluated for CAD suspicion by coronary angiography were tested for CMV seropositivity and CRP levels. Fifty-six patients had normal coronary arteries and 123 patients had CAD. Six patients did not have anti-CMV antibodies and 87 of the 173 seropositive patients had high levels of anti-CMV antibodies (≥ 8 U/mL). High CMV seropositivity (≥ 8 U/mL) was a significant CAD determinant even after adjustment for traditional CAD risk factors (odds ratio {OR} = 2.1 P = 0.04, respectively). The results indicate that the prevalence of high CMV seropositivity is an independent predictor of CAD in our study population and that our study population with CAD had a high rate of CMV infection. (Int Heart J 2005; 46: 205-209) 
that this condition was a determinant of coronary artery disease (CAD). [9] [10] [11] [12] The purpose of this study was to investigate both the prevalence of the CMV infections in our study population and whether high CMV seropositivity is a determinant of CAD.
METHODS
Study subjects : The study population consisted of a total of 179 patients who had been suspected of having CAD and therefore subjected to diagnostic coronary angiography. The patients who had any angiographic evidence of atherosclerosis in their epicardial coronary tree, including a plaque, were classified as having CAD (CAD group). The patients who did not have any coronary lesions angiographically were classified as without CAD and served as the control group. Patients with acute coronary syndrome, unstable angina, or previous myocardial infarction were excluded from the study. Both groups were also subjected to a detailed evaluation for hypertension, diabetes mellitus, smoking habit, and hypercholesterolemia (> 200 mg/dL). The Ethical Committee of our institution approved the study and all patients provided written consent. Determination of CMV antibodies and CRP: Blood samples taken from the subjects to determine anti-CMV IgG and IgM antibody levels were centrifuged and kept at -20°C until assayed. All measurements were performed in duplicate to enhance the reliability of these measurements. CMV antibodies were determined using anti-CMV IgG and anti-CMV IgM ELISA antibody kits (DRG International, Inc., USA), and the seropositivity and high seropositivity limits of the anti-CMV IgG antibodies were taken as ≥ 1 and ≥ 8 U/mL, respectively, as recommended by the manufacturer. For IgM, values higher than the cut-off which equals a mean negative control OD 450 nm + 0.200 were considered positive. CRP levels were assayed using an immunonephelometry system (Dade Behring), and an elevated CRP value was taken as being equal to or higher than 6 mg/L, as recommended by the manufacturer. Statistical analysis: The software program SPSS for Windows 10.0 was used. Continuous variables are presented as the mean ± SD. Categorical variables are presented as frequencies and percentages, and were analyzed using the chi-square test. The differences between the continuous variables were analyzed using the Mann-Whitney U test. The odds ratio (OR) in logistic regression analysis was used as a measure of the risk of CAD in patients with a given risk factor as compared to those without that factor. CRP level and traditional risk factors for coronary artery disease, including age, sex, hypertension, diabetes mellitus, smoking habit, and hypercholesterolemia, were used as covariants for adjustment in logis-Vol 46 No 2 tic regression analysis. The correlations were tested using the Spearman coefficient. A P value of < 0.05 was considered statistically significant.
RESULTS
The CAD group consisted of 123 (69%) patients, of whom 27 (22%) were female and 96 (78%) male. The mean age was 56 ± 10 years. The group without CAD consisted of 56 (31%) patients, of whom 31 (55%) were female and 25 (45%) male. The mean age was 54 ± 11 years.
Six patients (3%) did not have anti-CMV IgG antibody and no patients had anti-CMV IgM antibody. Of the 173 (97%) patients who had positive tests for anti-CMV IgG antibodies, 87 (49%) had high levels of IgG antibodies.
The traditional risk factors, mean CRP levels, and the prevalence of the high CMV seropositivity were compared between the patients with and without CAD ( Table I) . Smoking habit, male gender, mean CRP level, and the prevalence of the high CMV seropositivity were significantly higher in the CAD group (P < 0.01, 0.01, 0.001, 0.045, respectively). The relationship of high CMV seropositivity to CRP in the CAD group was also evaluated, and a significant correlation was found (r = 365, P = 0.03).
The correlations between CAD and high CMV seropositivity, CRP levels, and the traditional risk factors are shown in Table II . Univariate analyses revealed the presence of CAD was significantly associated with high CMV seropositivity (R: 0.150, P = 0.045). After adjustment for the mean CRP level and traditional CAD risk factors, including age, gender, smoking, diabetes, hypertension and hypercholesterolemia, high CMV seropositivity remained significant (OR = 2.1, P = 0.04), suggesting that high CMV seropositivity is an independent determinant of CAD. 
DISCUSSION
The prevalence of infection within a community varies with socioeconomic status, being as low as 40% in upper strata and approaching 100% in lower groups. 13) Our study population had a high rate of CMV infection. This can be explained by the socioeconomic status and the CAD study patients selected. Similar ratios have been found in Spain also. 14) It has been proposed that monocytes may deliver latent CMV locally to the site of vascular injury, where constituents of the vessel wall can enhance CMV IE gene expression and thereby contribute to viral reactivation and/or replication. The virus could then stimulate immune and inflammatory responses that could further contribute to the atherogenic process taking place in the vessel wall. 15, 16) Therefore, in light of the existing literature, it is possible to say that the CRP level and the level of CMV seropositivity might be higher during CMV reactivation and CAD. A multitude of epidemiological studies also report that CRP and high CMV seropositivity, claimed to be a sign of reactivation, are major risk factors for CAD. [17] [18] [19] [20] In the present study we found that the prevalence of high CMV seropositivity was greater in the group with CAD, and that in the multivariate analyses this is a predictor of CAD, independent of CRP levels and other traditional CAD risk factors.
In conclusion, the results indicate that the prevalence of high CMV seropositivity is an independent predictor of CAD in the present study population and that our study population with CAD had a high rate of CMV infection. Since such a relationship having its basis in serology may be misleading, studies with similar designs in which CMV antigens are also included should be performed. 
